Non-cancer drugs that target a homologous underlying biological mechanism or mutation can be repurposed to treat cancer. For example, Raloxifene was originally developed as a treatment for osteoporosis but has been used to reduce the risk of breast cancer in high-risk women. Alternatively, an existing cancer drug can be used to treat cancer in a different organ if it is caused by the same mutation or disruption of the same mechanism. For example, Tamoxifen was originally developed as a treatment for breast cancer but has been used to treat other types of cancer, such as ovarian and endometrial. Learn more about drug repurposing in oncology through this collaborative project between Elsevier and the Sinergia Consortium, focusing on diffuse intrinsic pontine glioma (DIPG), a rare form of childhood brain cancer.